Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEASE: ALK-001 in Stargardt Disease
NCT02402660Phase 2Active, not recruiting
- Sponsor
- Alkeus Pharmaceuticals, Inc.
- Start
- Aug 2015
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gildeuretinol in Stargardt disease (STGD), sponsored by Alkeus Pharmaceuticals, Inc.. Started Aug 2015; status: active, not recruiting.
02
Drugs
gildeuretinol
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT02402660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02402660.